Investor Presentaiton
Out-licensing Focus: Henlius' International Quality Biosimilars Scale up
across the Globe
Market Size of Originators and Marketed Biosimilars
Biosimilars with existing out-licensing partners
Global sales in 2023 (M USD)
Biosimilars to be out-licensed ex-China
Global sales in 2023 (M USD)
EU, US, CAN, ASEAN, MENA, etc. with
accord XKGbio Abbott
Eurofarma E Elea
The Evolution of Generics
Broadening horizons
HLX14-
Denosumab
HLX02-
Trastuzumab
HER2
9,274
RANKL
HLX11-
Pertuzumab
6,726
Global with
HER2
3,947
Organon
O Global with
Organon
HLX03-
Adalimumab
TNF-α
16,002
ASEAN, MENA, etc. with
HLX01-
Rituximab
CD20
3,888
HLX04-
Bevacizumab
VEGF
3,381
MENA, LATAM etc. with
Boston
Oncology™
Eurofarma
Broadening horizons
FARMA
DE COLOMBIA
Abbott
LATAM, etc. with
→Eurofarma
Broadening horizons
Potentially first biosimilar in
EU and the US
Global potentially
first biosimilar
20
Data Source: Global data
GGetz
pharma
O 2024 Henlius.
1
I
1
I
HLX15-
Daratumumab
CD38
9,744
HLX17-
Pembrolizumab
PD-1
25,087
HLX13-
Ipilimumab
CTLA-4
2,238
HLX05-
Cetuximab
EGFR
1,678
HLX12-
Ramucirumab
VEGFR-2
1,013
A Henlius 复宏汉霖View entire presentation